{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"The percent of pts with confirmed Objective Disease Response (confirmed best responses of complete response \\[CR\\], clinical complete response \\[CCR\\], or partial response \\[PR\\]). Responses were evaluated according to a composite assessment (Objective Primary Disease Response Evaluation Criteria - OPDREC).","groups":[{"description":"Regimen was 14 mg/m2 IV over a 4-hour period on Days 1, 8, and 15 of a 28-day cycle. The protocol included 6 cycles of treatment; responding patients and patients who achieved at least Stable Disease (SD) had the option of continuing treatment beyond 6 cycles at the discretion of the Investigator and based on local regulations.","id":"OG000","title":"Romidepsin"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis based on interim analysis of data for as treated population","reportingStatus":"POSTED","timeFrame":"6 months","title":"The Percent of Patients (Pts) With Objective Disease Response","type":"PRIMARY","unitOfMeasure":"Percent of participants"}